Harmony Biosciences Holdings (HRMY) Consolidated Net Income (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Consolidated Net Income data on file, last reported at $32.5 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income fell 28.69% year-over-year to $32.5 million; the trailing twelve-month figure through Mar 2026 stood at $188.4 million (up 23.36% YoY), and the FY2025 full-year result was $201.5 million, up 38.47% from the prior year.
• Consolidated Net Income fell to $32.5 million in Q1 2026, from $65.3 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $87.9 million in Q3 2022 to a low of $11.6 million in Q2 2024.
• A 5-year average of $40.6 million and a median of $38.5 million in 2023 frame the typical range for Consolidated Net Income.
• Across the five-year window, Consolidated Net Income surged 1014.17% in 2022 and sank 66.21% in 2024, its largest moves.
• Tracing HRMY's Consolidated Net Income over 5 years: stood at $48.5 million in 2022, then slumped by 45.15% to $26.6 million in 2023, then surged by 85.95% to $49.5 million in 2024, then soared by 31.91% to $65.3 million in 2025, then plunged by 50.22% to $32.5 million in 2026.
• Business Quant data shows HRMY's Consolidated Net Income at $32.5 million in Q1 2026, $65.3 million in Q4 2025, and $50.9 million in Q3 2025.